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Summary 
Few studies have examined the relationship between inflamma-
tory biomarker blood levels, cardioembolic stroke subtype and 
neurological deficit. So the aim of our study is to evaluate plas-
ma levels of immuno-inflammatory variables in patients with car-
dio-embolic acute ischaemic stroke compared to other diag-
nostic subtypes and to evaluate the relationship between immu-
no-inflammatory variables, acute neurological deficit and brain 
infarct volume. One hundred twenty patients with acute is-
chaemic stroke and 123 controls without a diagnosis of acute is-
chaemic stroke were evaluated. The type of acute ischaemic 
stroke was classified according to the TOAST classification. We 
evaluated plasma levels of IL-1β, TNF-α, IL-6 and IL-10, E-selec-
tin, P-selectin, sICAM-1,sVCAM-1, vWF, TPA and PAI-1. Patients 
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with ischaemic stroke classified as cardio-embolic (CEI) showed, 
compared to other subtypes, significantly higher median plasma 
levels of TNF-α , IL-6 and IL-1β. Furthermore stroke patients 
classified as lacunar showed, compared to other subtypes, signifi-
cantly lower median plasma levels of TNF-α, IL-6 and IL-1β. 
Multiple linear regression showed a significant association be-
tween the Scandinavian Stroke Scale (SSS) score at admission 
and diagnostic subtype, infarct volume of cardio-embolic strokes 
and some inflammatory variables. Our findings confirm that car-
dio-embolic strokes have a worse clinical presentation and pro-
duce larger and more disabling strokes than other ischaemic 
stroke subtypes reporting a possible explanation of higher im-
muno-inflammatory activation of the acute phase.  
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Introduction  
The prevalence of cardio-embolic stroke is increasing as the 
population of patients with atrial fibrillation (AF) is growing 
markedly with the increasing number of the elderly (1). In gen-
eral, the prognosis of cardio-embolic stroke tends to be poor as a 
result of obstruction of the major brain arteries by large fibrin-
rich thrombi to produce large brain infarcts (2). Cerebral ischae-
mia initiates a complex cascade of events at genomic, molecular, 
and cellular levels, and inflammation is important in this cas-
cade, both in the central nervous system (CNS) and in the pe-
riphery (3, 4). Furthermore, recent research points to the role of 
chemokines, normally key factors in inflammation, in thrombo-
genesis (5), probably also explaining hyper-responsiveness of 
platelets in ischaemic stroke (6). Recently our group reported 
that lacunar strokes compared to non-lacunar ones exhibited sig-
nificantly lower plasma levels of tumour necrosis factor 
(TNF)-α and interleukin (IL)1-β, P-selectin and intercellular ad-
hesion molecule 1 (ICAM-1) 24–72 hours (h) and 7–10 days 
after stroke onset (7). One previous study examined inflamma-
tory pathways in lacunar study (8), whereas no study, to our 
knowledge, evaluated inflammatory pathways in acute cardio-
embolic strokes. Furthermore, few studies have examined the re-
lationship between blood levels of inflammatory biomarkers and 
stroke outcome (9, 10), but data on a relation between inflam-
mation parameters and diagnostic subtype remain scarce.  
So the aim of our study is to evaluate cytokines, selectins and 
adhesion molecule plasma levels in patients with acute is-
chaemic stroke in relation to diagnostic subtype and to evaluate 
the relationship between clinical, laboratory and immuno-in-
flammatory variables and acute neurological deficit. We chose to 
evaluate these biomarkers because acute ischaemic stroke has 
been associated with serum elevations of a series of immuno-in-
flammatory variables such as TNF-α, IL-6, IL1-β, selectins and 
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adhesion molecules (11–14) and of markers of impaired hae-
mostasis and thrombosis (15–18). Thus, it appears that inflam-
mation, mediated by both molecular components, including cy-
tokines, selectins and adhesion molecules and cellular com-
ponents, such as leukocytes and microglia may be important in 
the mechanisms of cerebral injury and repair. So it may be useful 
evaluate immuno-inflammatory and thrombotic-fibrinolytic 
variables in acute ischaemic stroke and to evaluate their relation 
with acute neurological deficit and stroke volume. 
Materials and methods  
Patient population  
We enrolled all consecutive patients with a diagnosis of acute is-
chaemic stroke admitted to the Internal Medicine and Cardio-
Angiology Department at the University of Palermo (Italy) be-
tween November 2002 and January 2006. Controls were patients 
admitted, in the same period, to our department for any cause 
other than acute cardiovascular and cerebro-vascular events or 
exclusion criteria (see exclusion criteria section).  
Stroke was defined by focal neurological signs or symptoms 
thought to be of vascular origin that persisted for >24 h confirm-
ed by brain computed tomography (CT) and /or magnetic reson-
ance imaging (MRI) scan in baseline conditions and brain CT 
with contrast medium after 48–72 h (19). 
In order to also match patients with acute ischaemic stroke 
and controls for cardiovascular risk and previous cardiovascular 
morbidity, controls were included if they had vascular risk fac-
tors or a history of myocardial infarction or cerebrovascular dis-
ease or peripheral vascular disease, but they were excluded if 
they had either current or recent (up to six months) cerebro-vas-
cular disease or one of the exclusion criteria (see exclusion crite-
ria section).  
Cardiovascular risk factors were evaluated for both subjects 
and controls on the basis of the following criteria:  
– Hypercholesterolemia was defined as the presence of total 
cholesterol blood levels ≥200 mg/dl. Hypertension was de-
fined as present if subjects had been previously diagnosed 
according to the World Health Organization/ International 
Society of Hypertension guidelines and were routinely re-
ceiving antihypertensive therapy.  Patients were defined as 
type 2 diabetics if they had known diabetes treated by diet, 
oral hypoglycaemic drugs or insulin before stroke.  
– Previous coronary artery disease was determined on the basis 
of a history of physician-diagnosed angina, myocardial in-
farction, or any previous revascularisation procedure as-
sessed by a questionnaire 
– Previous cerebrovascular disease (transitory ischaemic at-
tack [TIA]/ischaemic stroke) was assessed by history, spe-
cific neurologic examination executed by specialists, and 
hospital or radiological (brain CT or MRI scan) records of 
definite previous stroke. 
– Subjects were classified as having previous peripheral artery 
disease (PAD) when they had a history of arterial brachial 
index (ABI) <0.9 and/or of claudicatio intermittens or of 
critical limb ischaemia or when they had undergone a periph-
eral arterial bypass surgery or amputation. 
 
Since several drugs commonly used by subjects suffering from 
hypertension, diabetes, and hypercholesterolemia display anti-in-
flammatory properties, we took into account at the time of re-
cruitment if patients enrolled are being treated with these drugs. 
The study protocol was approved by the local ethics commit-
tee, and all participants ( or the nearest relative when patients 
were unable) gave written informed consent . 
Every subject with ischaemic stroke was matched for age (± 
3 years), sex, and cardiovascular risk factor prevalence with one 
control subject . 
Patients with inflammatory or infectious diseases, auto-
immune and rheumatic diseases, cancer, haematological dis-
eases and severe renal or liver failure, as well as those who were 
under treatment with anti-inflammatory drugs, were excluded. 
We also excluded patients with fever and recent venous throm-
boembolism .  
The type of acute ischaemic stroke was classified according 
to the TOAST classification (20): 1) Large Artery Athero-
Sclerosis (LAAS); 2) Cardio-Embolic Infarct (CEI); 3) LACu-
nar infarct (LAC); 4) stroke of Other Determined Etiology 
(ODE); 5) stroke of UnDetermined Etiology (UDE).  
Clinical and instrumental evaluation  
All the ischaemic stroke patients underwent: medical history 
with recording of potential stroke risk factors, blood and coagu-
lation tests, 12-lead electrocardiogram (ECG), 24-h electroc-
ardiography monitoring, transthoracic echocardiography, caro-
tid ultrasound, brain CT scan at admission ( in some cases re-
peated at 4–7 days) . 
Blood samples  
Blood samples were obtained in the non-fasting state. After 10 
minutes of rest in the supine position, vital signs were recorded 
and blood samples were collected from the antecubital vein. 
EDTA-anticoagulated peripheral blood was drawn from each 
patient within 12 h of symptom onset. Serum and plasma were 
immediately separated by centrifugation and stored in aliquots at 
–80°C until analysis.  
Biochemical evaluation of immuno-inflammatory 
variables  
We evaluated plasma levels of IL1-β, TNF-α, IL-6 and IL-10, 
E-selectin, P-selectin, sICAM-1 and sVCAM-1 as markers of 
immuno-inflammatory activation, von Willebrand factor (VWF) 
plasma levels as a marker of endothelial dysfunction and platelet 
activity, tissue plasminogen activator (TPA) antigen and plasmi-
nogen activator inhibitor (PAI)-1 plasma levels as thrombotic/ fi-
brinolytic markers.  
IL1-β, TNF-α, IL-6 and IL-10 and VWF antigen were 
measured using a sandwich ELISA (Human IL-1β, TNF-α, IL-6 
and IL-10 Quantikine, R&D Systems; VWF ELISA kitdurian, 
Instrumentation Laboratory, Milano, Italy); VCAM-1, ICAM-1, 
E-selectin, P-selectin, PAI-1 and TPA-antigen were measured by 
commercial bioimmunoassay (Human sICAM-1, sVCAM-I, sE-
selectin and sP-selectin Parameter, Quantikine, R&D Systems; 
Gentaur AssayMax Human Plasminogen Activator Inhibitor-1 
(PAI-1) ELISA Kit, Gentaur AssayMax Tissue Plasminogen Ac-
tivator (TPA) ELISA Kit). 
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The minimum detectable concentrations for the diagnostic 
tests are: TNF-α: 1.6 pg/ml; IL1-β: <1 pg/ml; IL-6: <0.70 pg/ml; 
IL-10: >3.9 pg/ml; ICAM-1:< 0.35 ng/ml; VCAM-1: 0.6 ng/ml; 
E-selectin: <0.1 ng/ml; P-selectin: < 0.5 ng/ml; VWF: 1.0%; 
TPA: 0.3 pg/ml; PAI-1:< 50 pg/ml.  
Intraassay and interassay coefficients of variation were: 
TNF-α: 4.2% and 4.6%; IL1-β: 3.3% and 4.2%; IL-6: 1.6% and 
3.3%; IL-10: 4.3% and 7.5%; ICAM-1: 4.8% and 6.1%; 
VCAM-1: 3.5% and 7.7%; E-selectin: 4.8% and 5.7%; P-selec-
tin: 4.9% and 8.8%; VWF: 5% and 10%; TPA: 4.8% and 5%; 
PAI-1: 5.7% and 8.3%.  
Table 1: Demographic, clinical and im-
munoinflammatory variables and anti-
thrombotic and cardiovascular medi-
cations for stroke patients and controls. 
Variable Stroke patients 
(n = 120) 
Controls 
(n = 123) 
P-value 
Age (years)    72 (64–82.5)   69 (65–83) 0.749 
Glucose blood levels (mg/dl)   145.5 (99–233)  119 (87.5–143.5) 0.001 
Cholesterol blood levels (mg/dl)   232 (199–260)  201 (178–225) <0.001 
Triglycerides (mg/dl)  187.5 (140.75–211.75)  154 (98–200) 0.007 
White body cells (WBC) (per mm³)  8000 (6700–10000) 6400 (5500–8800) <0.001 
Neutrophils (%)  5780 (4071–8000) 3843 (336–6320) <0.001 
CRP (mg/dl)     3.5 (1.2–4.6)    1.3 (0.8–1.5) <0.001 
Sex (M/F)    68/52   55/68 0.062 
Diabetes (n/%)   50 (41.7)   59 (48%) 0.363 
Statins (n/%)   41 (34.16%)   44 (35.7%) 0.23 
ACE inhibitors (n/%)   47 (39.1%)   49 (39.8%) 0.23 
Angiotensin-receptor blockers, (ARBs) (n/%)   27 (22.5)   29 (23.5) 0.25 
Antidiabetic drugs (n/%)  
– Biguanids (n/%) 
– Sulphonilureas (n/%) 
– Thiazolidinediones (n/%) 
 
  18 (15)  
  12 (10) 
   4 (3.3) 
 
  21 (17.5) 
  14 (11.6) 





Insulin (n/%)   16 (13.3)   19 (15.44) 0.60 
Demographic and anamnestic variables are expressed as n° (percentage). Laboratory variables are expressed as median and interquar-
tile (lower and upper quartile). WBC: white body cell count; CRP: C-reactive protein; CAD: coronary artery disease; CHF: congestive 
heart failure; PAD: peripheral artery disease; TNF-α: tumour necrosis factor α; IL-1 β: interleukin-1-β; IL-6: interleukin-6; IL-10: inter-
leukin 10; ICAM-1: intercellular adhesion molecule-1; V-CAM-1: vascular cell adhesion molecule-1; vWF: von Willebrand factor; TPA: 

















 Hypertension (n/%)   74 (61.7%)   77 (62.6%) 0.101 
 Previous stroke (n/%)   39 (32.5 )   37 (30.08 ) 0.75 
 CAD (n/%)   25 (20.8 )   24 (19.5 ) 0.46 
 PAD (n/%)   14 (11.6 )   17 ( 13.8 ) 0.23 
 IL-1β (pg/ml)     9 (4–11)    3 (2–5) <0.001 
 IL-6 (pg/ml)   11 (6–30)    9 (2.9–18) <0.001 
 TNF-α (pg/ml)   31.5 (10.25–41)    3.7 (1.1–4.3) <0.001 
 E-selectin (ng/ml)    2.25 (2.0–4.0)    2 (1–2) <0.001 
 P-selectin (ng/ml)    4 (2–6.3)    3.1 (2.1–4) 0.004 
 VICAM (ng/ml)   20 (15.1–23)   14 (13–17) <0.001 
 ICAM (ng/ml)   20.8 (16.2–24)   15.9 (12–18.1) <0.001 
 IL-10 (pg/ml)    3.75 (2–9)    4 (2–10) 0.433 
 vWF (ng/ml)   10 (6–10)    4 (3–8) 0.0001 
 PAI-1 (pg/ml)   142 (109.5–175)   21 (12–26) <0.001 
 TPA (pg/ml)    24 (15.75–36)   74 (59–98) <0.001 
 Premorbid antithrombotics 
 Antiplatelet drugs (n/%)   36 (30)   35 (29.1) 0.56 
 Anticoagulants (n/%)   38 (31.6)   56 (45.5) 0.23 
 Premorbid cardiovascular drugs    
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Ischaemic brain lesion volume  
Brain CT was routinely performed on patient admission and re-
peated (in some cases) at 4–7 days (mean 4.5 days) after stroke 
onset. 
Each scan was performed with 120 kV, 160 mA, 5 mm thick-
ness and 2 seconds acquisition time. We used a time-consuming 
but accurate technique for calculating the volume of ischaemic 
brain lesion according to the Cavalieri principle (20). With this 
method we avoided imprecise estimations of the lesion volume 
due to the different three-dimensional form of the lesion itself 
(pyramidal or ellipsoid). In detail, for each CT slice in which the 
ischaemic lesion appeared, we calculated the surface of the 
lesion (mm2). In the same slice we multiplied the lesion surface 
by 5, a number expressing the CT axial sections thickness of 5 
mm each, to obtain the volume (3 mm) on the given CT slide. 
Subsequently, for each patient we summed the volumes of the in-
dividual slices where the lesion appeared.  
Acute neurological deficit evaluation 
Neurological deficit score on admission was evaluated by Scan-
dinavian Stroke Scale (SSS). SSS assesses neurological deficit 
through an evaluation of consciousness level, eye movement, 
strength in arms, hands, and legs, orientation, language, facial 
weakness and gait, giving rise to a score ranging from 58 (ab-
sence of deficit) to 0 (death)  
Statistical analysis  
Data are reported as median (lower Quartile<-> upper Quartile). 
Comparisons between groups were performed by Mann-Whit-
ney U test. The Kruskal-Wallis test was performed as non-para-
metric analysis of variance for multiple comparisons, and the 
Conover-Inman procedure was used as post-hoc test to make all 
possible pair-wise comparisons between groups. The Wilcoxon 
signed ranks test statistic was performed to compare controls 
with baseline data. Pearson Chi-Square was computed for cat-
Table 2: Demographic, clinical variables and antithrombotic and cardiovascular medication by ischaemic stroke TOAST subtype.  
Variable LAAS Lacunar CEI ODE P-value 
Number     50 (42%)   46 (38%)    20 (17%)     4 (3.3%)  
Age (years)    75 (66–86)   66.5 (60–76)    70 (64–81)    66.8 0.007 
Sex (M/F)     40/10   21/25    18/2     3/1 <0.0001 
Diabetes (n/%)     12 (24%)   31 (67%)     7 (35%) - <0.0001 
Hypertension (n/%)    29 (58%)   27 (59%)    14 (70%) - =0.623 
Hypercholesterolaemia (n/%)    28 (56%)   15 (33%)     5 (25%) - =0.034 
Previous TIA (n/%)    24 (48%)   22 (48%)    11 (55%) - =0.9206 
Previous stroke (n/%)     28 (56%)   15 (33%)    10 (50%)     2 (50) =0.0651 
Glucose blood levels (mg/dl)    117 (96–226)  167.5 (101–244)   109 ( 87–199)    96 (77–142) <0.0001 
WBC (cell/μl)  9010 (8000–10500) 7850 (6500–9200) 10250 (8700–12000)  9500 (8300–11000) 0.033 
ACE inhibitors (n/%)    20 (40)   18 (39.1)     9 (45)     1 0.071 
Angiotensin-receptor blockers, (ARBs) (n/%)    11 (22)   11 (23.9)     5 (25)     1 0.54 
Antidiabetic drugs 
– Biguanids (n/%) 
– Sulphonilureas (n/%) 
– Thiazolidinediones (n/%) 
 
    4 (8 ) 
    3 (6) 
    1 (2) 
 
  10 (21.71 ) 
   9 (19.56 ) 
   2 (4.34 ) 
 
    4 (20) 






Insulin (n/%)     4 (8 )   10 (21.71)     2 (10) - <0.05 
Demographic and anamnestic data are expressed as n° (percentage). Laboratory variables are expressed as median and interquartile (lower and upper quartile). TOAST: Trial of Org 10172 in Acute Stroke Treat-
ment WBC: white body cell count; CRP: C-reactive protein; CAD: coronary artery disease; CHF: congestive heart failure; previous TIA: previous transitory 

















 CRP (mg/dl)     3.2 (1.3–4.0)    3.1 (1.4–4.1)     3.4 (1.5–4.3)     3 (1.5–3.9) 0.35 
 CAD (n/%)     17 (33)   14 (30.4)     5 (25)     0 =0.024 
 CHF (n/%)     6 (12)   11(23.9)     4 (20)     0 =0.05 
 SSS score (median)     36 (29–39)   49.5 (47–50.7)    29 (11–34)    33 (31–10) <0.0001 
 Ischaemic brain volume lesion (mm3)  11894 (±2100) 9894 (±1200) 12273(±2400) 10273(±1800) =0.024 
 Premorbid antithrombotics 
 Antiplatelet drugs (n/%)    21(42)    9 (19.5)     5 (25)     1 (25) <0.0001 
 Anticoagulants (n/%)     5 (10)   18% (39.1)    11 (55)     4 <0.0001 
 Premorbid cardiovascular drugs 
 Statins (n/%)    17 (34.8)   16 (34.7)     7 (35) - 0.38 
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egorical variables. A two-tailed p-value <0.5 was considered 
statistically significant.  
Multiple linear regression was performed to investigate as-
sociations between some relevant variables and SSS score as a 
dependent variable.  
According to sample size calculation a sample size of 110 pa-
tient-control pairs had 80% power at the 5% significance level to 
detect a 10% difference in selected biomarker plasma levels be-
tween control subjects and patients and between each subtype of 
stroke.  
Results  
We enrolled 156 subjects with acute ischaemic stroke and 123 
matched controls (without ischaemic stroke). We excluded 36 
subjects for one or more exclusion criteria (6 for rheumatologic 
disease, 6 for infectious diseases; 10 for previous treatment with 
anti-inflammatory drugs; 8 for fever and 6 for cancer). The final 
sample consisted of 120 subjects with acute ischaemic stroke. 
Demographic, clinical, laboratory and immuno-inflammatory 
variables of patients with acute ischaemic stroke and controls are 
shown in Table 1.  
Among stroke patients, according to TOAST Classification, 
50 were classified as LAAS, 46 as lacunar, 20 as CEI and 4 as 
ODE. 
Stroke patients compared to controls showed significantly 
higher median plasma levels of IL1-β, IL-6, TNF-α, E-selectin 
P-selectin V-CAM-1 and ICAM-1 ( see Table 1).  
Demographic, laboratory and clinical variables of stroke pa-
tients in relation to TOAST subtype are listed in Table 2. The 
median time of blood sampling was 36 h (8–48 h). Among sub-
jects with acute ischaemic stroke classified as LAAS, 40 were 
male and 10 female, 12 (24%) were diabetic, 29 (58%) had hy-
pertension, 28 (56%) had hypercholesterolaemia, 24 (48%) had 
a previous TIA and 28 (56%) a previous stroke, 17 (33%) had a 
previous diagnosis of CAD and six (12%) a previous diagnosis 
of congestive heart failure (CHF) ( see Table 2). Among subjects 
with acute ischaemic stroke classified as cardio-embolic, 18 
were male and two female, seven (35%) were diabetic, 14 (70%) 
had hypertension, five (25%) had hypercholesterolaemia, 11 
(55%) had a previous TIA and 10 (50%) a previous stroke, 5 
(25%) had a previous diagnosis of CAD and 4 (20%) a previous 
diagnosis of CHF (see Table 2).  
Among subjects with lacunar stroke, 21 were male and 25 fe-
male, 31 (67%) were diabetic, 27 (59%) had hypertension, 15 
(33%) had hypercholesterolaemia, 22 (48%) had a previous TIA 
and 15 (33%) a previous stroke, 14 (30.4) had a previous diag-
nosis of CAD and 11(23.9) a previous diagnosis of CHF (see 
Table 2).  
In Table 2 we also reported any difference in use of drugs 
such as statins, sulphonilurea metfomin, thiazolidinediones, 
ACE-inhibitors, angiotensin receptor blockers (ARBs) and other 
cardiovascular drugs among different stroke subtypes. 
The mean ischaemic lesion volume on brain CT was 1077.7 
mm3. The brain lesion mean volume was larger in patients with 
cardio-embolic stroke infarction (mean 12273 mm3) than in 
those with atherosclerotic lesions (mean 11894 mm3) and lacu-
nar infarct (mean 9894 mm3).  
Interestingly, patients with cardio-embolic subtype showed a 
significantly lower median SSS score [29 (11–34)] compared to 
other subtypes, whereas stroke patients classified as lacunar 
showed a significantly higher median SSS score [49.5 
(47–50.7)] ( see Table 1).  
Patients with ischaemic stroke classified as cardio-embolic 
(CEI), compared to other subtypes, showed significantly higher 
median plasma levels of TNF-α [38.5 (22.2–46) pg/ml; p< 
0.0001], IL-6 [11 (5.5–19) pg/ml; p=0.0029 ], IL1-β [11.5 
(8–13) pg/ml; p<0.0001] (see Fig. 1), whereas plasma levels of 
VWF in patients with cardio-embolic subtype were higher com-
pared to other subtypes but were only near statistical signifi-
cance [10 (5–12) ng/ml ( p= 0.0053)]. 
Furthermore, stroke patients classified as lacunar showed, 
compared to other subtypes, significantly lower median plasma 
levels of TNF-α [19.4 (9–23) pg/ml; p< 0.0001]; IL-6 [(4 (2–9) 
pg/ml ; p=0.0029) ], IL1-β [6 (10–3) pg/ml p< 0.0001 )] (see Fig. 
1), whereas plasma levels of VWF [6 (3–8) ng/ml (0.0057)] in 
Figure 1: TNF-α, IL-6 and IL1-β plasma 
levels in relation to TOAST subtype of is-
chaemic stroke. Data are expressed as medi-
an and interquartile (lower and upper quartile). 
TOAST = Trial of Org 10172 in Acute Stroke 
Treatment; TNF-a = tumour necrosis factor 
alpha; IL-6 = interleukin 6; IL-1b = interleukin 1 
beta. 
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patients with lacunar subtype were lower in comparison with 
other subtypes, but were only near statistical significance. 
Patients with LAAS subtype of acute ischaemic stroke com-
pared with subjects with cardio-embolic subtype had a lower 
mean brain infarct volume (11894 mm3 vs. 12273 mm3) and sig-
nificantly lower median plasma values of TNF-α [27.5 
(13.4–40.5) pg/ml vs. 38.5 (22.2–46) pg/ml] , IL-6 [8 (4–12) pg/
ml vs. 11 (5.5–19)pg/ml], IL1-β (9 (5–10.,5) pg/ml vs. 11.5 
(8–13) pg/ml] (see Fig. 1). No significative difference was ob-
served between each TOAST subtype with regard of ICAM-1, 
VCAM-1, E-selectin, P-selectin, VWF, PAI-1 and TPA plasma 
levels. 
Nevertheless comparing only the seven patients among 
LAAS and CEI strokes, that were comparable on the basis of 
matched mean brain infarct volume (11350 mm3 vs. 11455 
mm3), patients with cardio-embolic stroke showed similar medi-
an plasma levels of TNF-α [26.2 (11.4–37.5) pg/ml vs. 26.7 
(11.9–38.1 ) pg/ml, IL-6 [7 (3–11) pg/ml vs. 7.5 (5.5–13) pg/ml], 
IL1-β [10 (5–11.5) pg/ml vs. 11.5 (8–13) pg/ml] and similar 
mean SSS score (34 vs. 33).  
Infarct sites at brain CT in relation to TOAST diagnostic sub-
type are shown in Table 3. Interestingly, among patients with 
lacunar stroke no significant difference in median plasma levels 
of TNF-α, IL-6 and IL1-β was observed between subjects with 
and without a lacunar detectable lesion on neuroimaging (19.8 
pg/ml, 9 pg/ml and 6 pg/ml vs. 18.9, pg/ml, 10 pg/ml, 5.5 pg/ml, 
respectively; p = 0.87).  
Multiple linear regression performed to investigate associ-
ations between some relevant variables and SSS score as a de-
pendent variable showed a significant association between SSS 
score at admission and diagnostic subtype: lacunar (b=3.206; 
p=0.0338) ] or [cardio-embolic (b= –7.819; p = 0.0006)], infarct 
volume of cardio-embolic strokes and some inflammatory vari-
able [TNF-α (b =-0.013; p < 0.0001) or IL-6 (b= –0.074; p < 
0.000)1] see Table 4. 
Discussion 
Our findings show that among patients with acute ischaemic 
stroke, patients with cardio-embolic subtype showed signifi-
cantly higher plasma levels of TNF-α, IL-6 and IL1-β, whereas 
lacunar subtype showed significantly lower plasma levels of 
these cytokines.  
Our study further supports the hypothesis that inflammation 
may have an important role in the pathogenesis of ischaemic 
strokes, but our findings also suggest a peculiar immuno-inflam-
matory pattern in each subtype of acute ischaemic stroke.  
The first cells responding to brain ischaemia are glial cells, 
particularly microglia, with transcription of early pro-inflamma-
tory cytokines such as IL1-β and TNF-α able to activate addi-
tional inflammatory pathways leading to induction of nitric 
oxide, adhesion molecules and IL-6 (9, 10).  
Patients with cardio-embolic strokes, in comparison with 
other subtypes, showed a higher degree of acute neurological 
deficit at admission evaluated by SSS scale and a higher degree 
of immuno-inflammatory activation of the acute phase. On the 
other hand in patients with lacunar stroke, compared to other 
subtypes, we observed a lower degree of acute neurological defi-
cit at admission evaluated by SSS scale and a lower degree of im-
muno-inflammatory activation of the acute phase. Nevertheless 
patients with LAAS stroke subtype showed higher median plas-
ma levels of some immuno-inflammatory markers (TNF-α, IL-6 
and IL1-β) compared to lacunar subtype, but lower median plas-
ma levels of these biomarkers compared to the CEI subtype.  
 Large artery 
atherosclerosis 
strokes (n = 50) 
Cardioembolic 
strokes (n = 20) 
Lacunar strokes 
(n = 46) 
P-value 
Neuroimaging findings  
Cortical  31 (62%) 16 (80%)  8 (17.3%) <0.0001 
Subcortical 
– Internal capsula  
– Thalamus 
– Basal ganglia  
– Pons  
– Corona radiata 
19 (38%) 
10 (52.6%) 
 4 (21 %) 
 5 (26.3%) 
 0 
 0 
 4 (20%) 





28 (60. 8%) 
10 (35.7%) 
 7 (25%) 
 5 (21.7%) 
 2 (7.1%) 







No lesion CT- or  
MRI-detectable 
 0  0 10 (21%) <0.0001 







Table 3: Infarct site at neuroimaging find-
ings (brain CT or MRI) in relation of 
TOAST diagnostic subtype. 
Table 4: Multiple linear regression about association between 
immunoinflammatory and clinical variables and SSS score. 
IL-6  b1 = –0.074 p < 0.0001 
TNF-α b2 = –0.013 p < 0.0001 
Age  b3 = –0.121 p = 0.0596 
SBP  b4 = 0.078 p = 0.0603 
Previous stroke  b6 = –2.342 p = 0.0974 
TOAST subtype (lacunar)  b7 = 3.206 p = 0.0338 
TOAST subtype (cardioembolic)  b8 = –7.819 p = 0.0006 
Infarct volume of Cardioembolic Stroke  b8 = –6.519 p = 0.0218 
TNF-α: tumour necrosis factor α; IL-6: interleukin-6; SBP: systolic blood pressure; SSS: Scandinavian 
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Our finding concerning higher plasma levels of immuno-in-
flammatory markers in patients with cardio-embolic stroke 
underlines the role of inflammation in the pathogenesis of cer-
ebral cardio-embolism. Evidence is growing that inflammation 
may be associated with AF (22) and it may underlie pathogenesis 
of the arrhythmia (21, 22). Inflammation leads to the adhesion, 
recruitment and trans-endothelial migration of leucocytes into 
the intimae, which is mediated by adhesion molecules on the en-
dothelial cell membrane; leading to the initial capture and rolling 
of leucocytes along the endothelium (23). 
Patients with cardio-embolic stroke showed a significantly 
lower median SSS score compared to patients with other sub-
types of stroke, whereas patients with lacunar stroke showed a 
significantly higher SSS score compared to other clinical sub-
types of stroke. Moreover, on regression analysis stroke subtype 
(lacunar or cardio-embolic), infarct volume of cardio-embolic 
stroke and plasma levels of IL-6 and TNF-α were the variables 
most strictly associated with acute neurological deficit evaluated 
by SSS score, with cardio-embolic subtype and higher plasma 
levels of these cytokines associated with a poor clinical presen-
tation (lower SSS score) and lacunar subtype and lower plasma 
levels of cytokines associated with a better clinical presentation 
(higher SSS score).  
Infarct size could represent a possible factor influencing im-
muno-inflammatory marker plasma levels, although this issue is 
not always confirmed (24–26), but it is conceivable that other 
factors could represent an additional factor that influence immu-
no-inflammatory activation after acute ischaemic stroke. Indeed 
ischaemic brain injury secondary to arterial occlusion is char-
acterized by acute local inflammation, which involves accumu-
lation of poly-morphonuclear neutrophils (PMN). Factors that 
influence the recruitment of PMN on infarct site could modify 
local cytokine production. Identification of factors involved in 
the selective recruitment and accumulation of inflammatory 
cells into ischaemic brain tissue is likely to expand our under-
standing of the mechanisms that result in transient or permanent 
neurological deficits, but the mechanisms behind the entry of 
leukocytes to sites of ischaemia are not well understood.  
Nevertheless in 25% to 40% of patients with ischaemic 
stroke, neurological symptoms progress during the initial hours 
(27, 28). Although several clinical, radiological, and biochemi-
cal factors have been associated with early neurological deterio-
ration, most of them have a low predictor value (29, 30). 
Our study showed a linear relationship between infarct volume 
and outcome only in patients with cardio-embolic stroke, whereas 
this relationship was not observed in patients with lacunar stroke in 
which we also did not observe any difference in immuno-inflam-
matory marker plasma levels in relation to the presence of detect-
able CT lesion. On regression analysis we also showed a significant 
relationship between some inflammatory markers (TNF-α, IL-6) 
and demographic variables (age), and diagnostic subtype (lacunar 
or cardio-embolic) and SSS score. Age is a widely described out-
come predictor, but particularly interesting is the apparent link be-
tween diagnostic subtype, immuno-inflammatory activation of the 
acute phase and outcome. In our study cardio-embolic strokes 
showed the highest degree of immuno-inflammatory activation of 
the acute phase and the lowest SSS score as an expression of a 
higher neurological deficit of the acute phase.  
This poor initial clinical presentation in terms of neurologi-
cal deficit of the acute phase of our patients with cardio-embolic 
strokes coincides with Sherman’s opinion (31) that strokes re-
lated to AF are more often large and disabling compared to other 
causes of brain infarction.  
Moreover, Lin et al. (32) reported that ischaemic stroke as-
sociated with AF was nearly twice as likely to be fatal as non-AF 
stroke, whereas Jorgensen et al. (33) reported that functional 
deficits were more likely to be severe among survivors. This 
could probably be due to the larger median infarct volume of car-
What is known about this topic? 
− Cerebral ischaemia initiates a complex cascade of events 
at genomic, molecular, and cellular levels, and inflam-
mation is important in this cascade, both in the central 
nervous system (CNS) and in the periphery. 
− Recent research points to the role of chemokines, norm-
ally key factors in inflammation, in thrombogenesis, 
probably also explaining hyper-responsiveness of pla-
telets in ischaemic stroke. 
− Recently our group reported that lacunar strokes com-
pared to non-lacunar ones exhibited significantly lower 
plasma levels of TNF-α and IL-1β, P-selectin and 
ICAM-1 24–72 hours and 7–10 days after stroke onset. 
− Few studies have examined the relationship between 
blood levels of inflammatory biomarkers and stroke out-
come , but data on a relation between inflammation pa-
rameters and diagnostic subtype remain scarce.  
 What does this paper add? 
− Our findings show that among patients with acute is-
chaemic stroke, patients with cardio-embolic subtype 
showed significantly higher plasma levels of TNF-α, IL-6 
and IL-1β, whereas lacunar subtype showed significantly 
lower plasma levels of these cytokines.  
− Our finding concerning higher plasma levels of immuno-
inflammatory markers in patients with cardio-embolic 
stroke underlines the role of inflammation in the patho-
genesis of cerebral cardio-embolism. 
− In our study we showed a linear relationship between in-
farct volume and outcome only in patients with cardio-
embolic stroke, whereas this relation was not observed in 
patients with lacunar stroke in which we also did not ob-
serve any difference in immuno-inflammatory marker 
plasma levels in relation to the presence of detectable CT 
lesion. 
− Infarct size could represent a possible factor influencing 
immuno-inflammatory marker plasma levels, although 
this issue is not always investigated and confirmed , but it 
is conceivable that other factors could represent an addi-
tional factor that influence immunoinflammatory acti-
vation after acute ischemic stroke. Indeed, ischaemic 
brain injury secondary to arterial occlusion is characte-
rised by acute local inflammation, which involves ac-
cumulation of polymorphonuclear neutrophils (PMN). 
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dio-embolic strokes as suggested by our findings of higher mean 
infarct volume and higher median TNF-α, IL-6 and IL1-β in sub-
jects with cardio-embolic stroke and of similar median plasma 
levels of these biomarkers and mean SSS score in patients of 
LAAS and CEI subtypes matched for similar infarct size.  
Possible limitations of the study are the fact that we have not 
evaluated neurobiochemical markers such as S100B (n:S100 
calcium binding protein B), NSE (neuron-specific enolase) or 
glial fibrillary acidic protein (GFAPI). S100B, however, is ex-
pressed not only in brain tissue but also in a variety of other cell 
types, under both physiological and pathological conditions. 
Moreover, S-100B expression in the latter conditions was far 
below the activity measured after acute central nervous system 
disorders and the brain specificity of S-100B release was ques-
tioned by a number of investigators, and specificity of NSE and 
GFAP in ischaemic stroke is not fully demonstrated. 
Single-point measurement could be another limitation of the 
study since repeated measures may be necessary to define the 
variance as well as the predictive nature of a biomarker, but in 
support for our findings, several studies previously reported the 
predictive value of single-point measurement of inflammatory 
biomarkers in AF (34) and other clinical conditions such as CHF 
(35) acute myocardial infarction (36). Morever, in further sup-
port of our single-point evaluation, Lynch et al. (37) recently re-
ported that two markers of inflammation and one marker of 
thrombosis are highly correlated with stroke at six and 24 h and 
that the extended time evolution of TNF-α response in humans, 
peaking at 2–3 days sustains our choice to evaluate biomarker 
plasma levels within 72 h of symptom onset.  
Regarding our patients with lacunar stroke, about 20% of our 
patients (see Table 4) did not have visible infarction on CT or 
MRI, which is similar to the results of previous studies (38, 39). 
Our patients with lacunar stroke with no lesion detectable on 
brain CT or MRI do not show any significant difference with re-
gard to cytokine plasma levels of the acute phase compared to 
patients with lacunar lesion (CT- or MRI-detectable). So beyond 
a possible direct relationship between infarct size and cytokine 
levels, infarct site could also have an additional role in immuno-
inflammatory activation of the acute phase. Interestingly, in our 
patients most of the lacunar strokes had a sub-cortical location, 
whereas most of the cardio-embolic strokes had a cortical lo-
cation (see Table 3). In particular in our patients with lacunar 
stroke and a sub-cortical location, most were located in basal 
ganglia and thalamus and only a minority in corona radiata. Sub-
cortical infarcts have been classified into two pathogenically dif-
ferent types: striatocapsular infarcts and terminal supply area in-
farcts (38, 39).  
On this basis, could the higher sub-cortical distribution of 
lacunar strokes with high percentage of striato-capsular infarcts 
and the higher cortical distribution of cardio-embolic and LAAS 
strokes explain our findings concerning the low immuno-in-
flammatory profile of acute lacunar strokes and the high immu-
no-inflammatory profile of LAAS and particularly of cardio-
embolic strokes? Is it plausible to hypothesize that cortical and 
sub-cortical sites could have a different resident immuno-in-
flammatory background? 
To our knowledge no study has addressed this issue, but sev-
eral recent studies suggested that neurons and astrocytes gener-
ate those cytokines after ischaemia (3). Moreover, two major cel-
lular components that migrated into the infarcted area to elimin-
ate tissue debris were macrophages and granulocytes (40). 
Nevertheless the precise derivation of microglia in the ischaemic 
regions, whether they arrive from the circulation or whether 
there are some differences with regard to microglial cell distribu-
tion between cortical and subcortical sites are important open 
questions that could, in our opinion, explain the different immu-
no-inflammatory pathway of the acute phase of lacunar strokes 
and that could provide ample basis for future studies. 
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